WFH Humanitarian Aid Program even more impactful in 2019

For many people with a bleeding disorder, access to care is a considerable daily challenge. The expanded WFH Humanitarian Aid Program aims to address this problem by providing patients—including children—with the support they need to lead normal lives. Thanks to the multi-year factor donations provided by our partners, people with bleeding disorders in the developing world have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and prophylaxis for young children.

The WFH Humanitarian Aid Program continues to have a real and sustained impact on the bleeding disorders community. Up until 2019, 19,792 patients have received treatment through the Program. Over 73 countries received donations, and nearly 120,000 infusions were given. Other encouraging news coming out of the efforts of the Program include the fact that 1,622 people were put on prophylactic treatment in 2019, of which 475 were under four years of age. Equally encouraging is the fact that 64,722 acute bleeds were treated last year, and 789 surgeries were completed thanks to the availability of donated product. In short, all the major metrics show marked improvements over the 2018 numbers, which were already very positive.

These significant results are a direct result of the donations provided by Sanofi Genzyme and Sobi. Their 5-year Visionary commitment of 500 million international units of clotting factor concentrates treatment products and their substantial financial support for the operational needs of the Program are having an important impact on people with hemophilia (PWH) in developing countries worldwide.

Kibet Shikuku, MD, Chairman, Kenya Hemophilia Association

“Right now, with the availability of product it’s much easier… to treat a bleed, prevent a bleed, and, where a bleed has caused some level of morbidly, we are actually able to make reversals.”

Just a few years ago, a diagnosis of hemophilia was almost a death sentence for patients. It meant that they would have a greatly reduced lifespan and quality of life, and it meant great hardship for parents. Thanks to the WFH Humanitarian Aid Program, there has been a complete shift in how patients are treated in developing countries. Patients—including children—are now able to get the treatment they need to live normal lives and be productive part of society.

Assad Haffar, WFH Director, Humanitarian Aid

“The WFH Humanitarian Aid Program is making a real change in the lives of people in the bleeding disorders community. It makes it possible to treat acute bleeds, perform life-changing surgeries, and, perhaps most encouragingly, it allows children to go to school, play with their friends and just feel normal.”

The WFH Humanitarian Aid Program also provides a range of integrated care development training programs for the healthcare providers who receive donated treatment product in order to ensure that donations are used as efficiently and effectively as possible.

The WFH Humanitarian Aid Program continues to give hope to bleeding disorders patients—often for the first time in their lives. The WFH will keep working with all our global partners to ensure that the WFH Humanitarian Aid Program continues to be successful.

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributor, CSL Behring.  To learn more about the WFH Humanitarian Aid Program, visit

HA Logo